Published in Eur J Pharmacol on June 12, 2008
Rapamycin induces Bad phosphorylation in association with its resistance to human lung cancer cells. Mol Cancer Ther (2011) 1.08
NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells. Int J Oncol (2014) 1.01
MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci (2012) 0.99
The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines. Invest New Drugs (2009) 0.97
miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer (2013) 0.97
Silencing of Twist1 sensitizes NSCLC cells to cisplatin via AMPK-activated mTOR inhibition. Cell Death Dis (2012) 0.88
Mammalian target of rapamycin and head and neck squamous cell carcinoma. Head Neck Oncol (2011) 0.86
The relationship of thioredoxin-1 and cisplatin resistance: its impact on ROS and oxidative metabolism in lung cancer cells. Mol Cancer Ther (2012) 0.85
N',N'-Dimethyl-N',N'-bis(phenylcarbonothioyl) Propanedihydrazide (Elesclomol) Selectively Kills Cisplatin Resistant Lung Cancer Cells through Reactive Oxygen Species (ROS). Cancers (Basel) (2009) 0.84
Cisplatin-induced apoptosis inhibits autophagy, which acts as a pro-survival mechanism in human melanoma cells. PLoS One (2013) 0.84
microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin. Oncol Lett (2013) 0.81
MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway. Tumour Biol (2015) 0.79
The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials. BBA Clin (2015) 0.75
Modulation of Bax and mTOR for cancer therapeutics. Cancer Res (2017) 0.75
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
TOR, a central controller of cell growth. Cell (2000) 10.41
Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene (2006) 3.39
When translation meets transformation: the mTOR story. Oncogene (2006) 2.21
Therapeutic targets: MTOR and related pathways. Cancer Biol Ther (2006) 1.57
Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry (Mosc) (2000) 1.52
Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol (2006) 1.43
Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood (1992) 1.43
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer (2005) 1.41
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther (2007) 1.22
Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther (2003) 1.12
Detection of 11q13 amplification as the origin of a homogeneously staining region in small cell lung cancer by chromosome microdissection. Genes Chromosomes Cancer (1996) 0.99
Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol (2003) 0.98
Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol (2003) 0.95
Overexpression of Cdk6-cyclin D3 highly sensitizes cells to physical and chemical transformation. Oncogene (2003) 0.90
Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells. Mol Cancer Ther (2004) 0.87
Telomerase: a potential therapeutic target for cancer. Expert Opin Ther Targets (2005) 0.83
2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res (2004) 2.88
Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol (2008) 2.33
DNA methylation: correlation with DNase I sensitivity of chicken ovalbumin and conalbumin chromatin. Nucleic Acids Res (1979) 2.31
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc (2004) 2.09
The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev (2007) 1.96
Differential nuclease sensitivity of the ovalbumin and beta-globin chromatin regions in erythrocytes and oviduct cells of laying hen. Nucleic Acids Res (1980) 1.91
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol (2005) 1.88
Arginine deprivation as a targeted therapy for cancer. Curr Pharm Des (2008) 1.82
Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther (2004) 1.82
Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J Biol Chem (2003) 1.78
Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol (2007) 1.63
Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol (2009) 1.63
Role of SIRT1 in regulation of LPS- or two ethanol metabolites-induced TNF-alpha production in cultured macrophage cell lines. Am J Physiol Gastrointest Liver Physiol (2009) 1.62
FGFR3 dimer stabilization due to a single amino acid pathogenic mutation. J Mol Biol (2005) 1.59
Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Ther (2007) 1.54
Molecular mechanisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. Alcohol (2004) 1.43
Adiponectin and alcoholic fatty liver disease. IUBMB Life (2008) 1.41
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer (2005) 1.41
Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs (2006) 1.39
Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/Sp4. Mol Cancer Ther (2009) 1.37
2-Deoxy-D-glucose activates autophagy via endoplasmic reticulum stress rather than ATP depletion. Cancer Chemother Pharmacol (2010) 1.35
Release of free bases from deoxyribonucleic acid after reaction with bleomycin. Mol Pharmacol (1972) 1.33
Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem (1996) 1.31
Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res (2012) 1.29
Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res (2003) 1.24
Localization of sequences specifying messenger RNA to light-staining G-bands of human chromosomes. Chromosoma (1977) 1.24
Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther (2007) 1.22
Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med (2010) 1.21
Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol (2002) 1.20
MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem (2012) 1.19
Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin. Mol Pharmacol (2009) 1.19
S-adenosylmethionine attenuates hepatic lipid synthesis in micropigs fed ethanol with a folate-deficient diet. Alcohol Clin Exp Res (2007) 1.17
Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol (2002) 1.15
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol (2003) 1.15
Regulation of hepatic lipin-1 by ethanol: role of AMP-activated protein kinase/sterol regulatory element-binding protein 1 signaling in mice. Hepatology (2011) 1.13
Critical role of FoxO3a in alcohol-induced autophagy and hepatotoxicity. Am J Pathol (2013) 1.13
MRP class of human ATP binding cassette (ABC) transporters: historical background and new research directions. Xenobiotica (2008) 1.10
Elevated glutathione levels confer cellular sensitization to cisplatin toxicity by up-regulation of copper transporter hCtr1. Mol Pharmacol (2008) 1.09
Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget (2010) 1.09
Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas (2005) 1.08
Specificity protein 1 (sp1) oscillation is involved in copper homeostasis maintenance by regulating human high-affinity copper transporter 1 expression. Mol Pharmacol (2011) 1.07
Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol (1990) 1.07
Transmembrane helix heterodimerization in lipid bilayers: probing the energetics behind autosomal dominant growth disorders. J Mol Biol (2006) 1.06
Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer (2012) 1.06
Preferential damage of active chromatin by bleomycin. Cancer Res (1981) 1.06
Synthesis and initial characterization of FGFR3 transmembrane domain: consequences of sequence modifications. Biochim Biophys Acta (2005) 1.06
Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res (2012) 1.05
Arginine deiminase resistance in melanoma cells is associated with metabolic reprogramming, glucose dependence, and glutamine addiction. Mol Cancer Ther (2013) 1.05
Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem (1998) 1.05
Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern--synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. Eur J Med Chem (2003) 1.03
Model for the formation of double minutes from prematurely condensed chromosomes of replicating micronuclei in drug-treated Chinese hamster ovary cells undergoing DNA amplification. Cancer Res (1989) 1.03
NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem (1997) 1.02
Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1. Oncogene (1999) 1.02
Mechanistic basis for overcoming platinum resistance using copper chelating agents. Mol Cancer Ther (2012) 1.01
Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol (2003) 0.98
Role of SIRT1-FoxO1 signaling in dietary saturated fat-dependent upregulation of liver adiponectin receptor 2 in ethanol-administered mice. Antioxid Redox Signal (2011) 0.97
Reusable platforms for high-throughput on-chip temperature gradient assays. Anal Chem (2002) 0.97
The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma. Drug Target Insights (2007) 0.96
Intrinsically lower AKT, mammalian target of rapamycin, and hypoxia-inducible factor activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther (2008) 0.96
Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol (1994) 0.95
Hepatic-specific lipin-1 deficiency exacerbates experimental alcohol-induced steatohepatitis in mice. Hepatology (2013) 0.95
Condensation of chromatin into chromosomes preserves an open configuration but alters the DNase I hypersensitive cleavage sites of the transcribed gene. Nucleic Acids Res (1982) 0.95
Multidrug resistance correlates with overexpression of Muc4 but inversely with P-glycoprotein and multidrug resistance related protein in transfected human melanoma cells. Biochem Pharmacol (2003) 0.95
2-acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. J Biol Chem (2001) 0.95
Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. Mol Carcinog (2006) 0.94
Ethanol administration exacerbates the abnormalities in hepatic lipid oxidation in genetically obese mice. Am J Physiol Gastrointest Liver Physiol (2012) 0.93
Direct interaction of proliferating cell nuclear antigen with the small subunit of DNA polymerase delta. J Biol Chem (2002) 0.93
Arthrobacter scleromae sp. nov. isolated from human clinical specimens. J Clin Microbiol (2005) 0.92
The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines. Biochem Biophys Res Commun (2010) 0.92
Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. J Biol Chem (1998) 0.92
Nucleic acid--specificity of bleomycin. Biochem Pharmacol (1972) 0.91
Bleomycin causes release of nucleosomes from chromatin and chromosomes. Nature (1978) 0.91
Merkel cell carcinomas. Hematol Oncol Clin North Am (2007) 0.91
Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology (1993) 0.91
Distribution of tightly bound proteins in the chicken ovalbumin gene region. Biochemistry (1982) 0.90
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs (2009) 0.89
Downregulation of adiponectin/AdipoR2 is associated with steatohepatitis in obese mice. J Gastrointest Surg (2009) 0.88
TSLC1 gene silencing in cutaneous melanoma. Melanoma Res (2010) 0.88
Identification and characterization of a hepatoma cell-specific enhancer in the mouse multidrug resistance mdr1b promoter. J Biol Chem (1995) 0.87
Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting. J Med Econ (2014) 0.87
Quantitative proteomic characterization of ethanol-responsive pathways in rat microglial cells. J Proteome Res (2013) 0.87
Location of messenger specifying sequences in mammalian chromosomes. Chromosoma (1977) 0.86
Abundancy and diversity of mRNA sequences in human leukocytes. Differentiation (1976) 0.86
Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Differ (1991) 0.86
Arginine deprivation in cancer therapy. Curr Opin Clin Nutr Metab Care (2015) 0.86
TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation. Mol Cell Biochem (2012) 0.85